The Food and Drug Administration (FDA) has approved Wegovy ® (semaglutide) tablets, the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity.

The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.

Pediatric patients aged 10 years and older with iron deficiency may now be treated with Accrufer following an expanded FDA approval.

Veligrotug, an IGF-1R inhibitor, is under FDA Priority Review for thyroid eye disease based on positive phase 3 trial data.

The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and ...

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.

Ceralasertib is an oral selective inhibitor of the ATR kinase, an important DNA-repairing protein in tumor cells.

Vaccination linked to lower risk for hospitalization, critical care unit admission, preterm birth during delta and omicron periods ...

(HealthDay News) — The US Food and Drug Administration (FDA) is weighing a change that could make warning labels on dietary supplements appear less often on packaging. Unlike prescription drugs, ...

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.

The Food and Drug Administration (FDA) has expanded the approval of Jascayd ® (nerandomilast), an oral phosphodiesterase 4 inhibitor, to include treatment of progressive pulmonary fibrosis (PPF) in ...

Bisphosphonates may reduce pain intensity in short term, but may result in little to no difference in immediate and medium term.